OSE Immunotherapeutics SA / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €17.33M -76.2% -€26.09M -209.2% -150.5% -1.8 pp N/A N/A
    (estimated) €72.74M +78.9% €23.89M +3,312.9% 32.8% +0.31 pp -€27.65M +185.1% -38.0% -0.14 pp
    (estimated) €40.66M -3.9% €700.00K +59.1% 1.7% +0.0068 pp -€9.70M +39.2% -23.9% -0.074 pp
    (estimated) €42.32M -39.4% €440.00K -98.8% 1.0% -0.53 pp -€6.97M -114.4% -16.5% -0.86 pp
    €69.88M +3,037.7% €37.45M -262.8% 53.6% +11 pp €48.52M -348.4% 69.4% +9.5 pp
    €2.23M -87.8% -€23.00M +29.5% -1,032.9% -9.4 pp -€19.53M +8.6% -877.1% -7.8 pp
    €18.30M -30.4% -€17.76M +5.4% -97.0% -0.33 pp -€17.98M +90.3% -98.2% -0.62 pp
    €26.31M +152.5% -€16.85M +1.8% -64.1% +0.95 pp -€9.45M -51.2% -35.9% +1.5 pp
    €10.42M -59.9% -€16.56M +255.9% -158.9% -1.4 pp -€19.34M -307.8% -185.6% -2.2 pp
    €25.95M +6.1% -€4.65M -184.7% -17.9% -0.40 pp €9.31M +457.3% 35.9% +0.29 pp
    €24.46M +266.0% €5.49M -152.3% 22.4% +1.8 pp €1.67M -121.9% 6.8% +1.2 pp
    €6.68M +1,644.6% -€10.50M -150.8% -157.2% -56 pp -€7.64M -1,170.4% -114.4% -3.0 pp
    €383.00K +9,475.0% €20.67M -470.1% 5,395.8% +1.4K pp €714.00K -115.6% 186.4% +1.1K pp
    €4.00K +∞% -€5.58M +97.0% -139,600.0% -1.4K pp -€4.57M +139.1% -114,275.0% -1.1K pp
    €0.00 +NaN% -€2.84M +1,034.0% N/A -€1.91M +710.2% N/A
    €0.00 +NaN% -€250.00K -82.6% N/A -€236.00K -83.1% N/A
    €0.00 -€1.44M N/A -€1.39M N/A

    Notifications